Rashtra NewsRashtra News
  • National
  • Business
  • Education
  • Entertainment
  • Finance
  • Insurance
  • Jobs
  • Sports
  • Stock Market
  • Technology
Notification Show More
Font ResizerAa
Rashtra NewsRashtra News
Font ResizerAa
  • National
  • Rashtra News Hindi
Search
  • National
  • Business
  • Education
  • Entertainment
  • Finance
  • Insurance
  • Jobs
  • Sports
  • Stock Market
  • Technology
Follow US
Rashtra News > Latest News > Business > Novavax says vaccine targeting Covid and flu shows promising results in early data
Business

Novavax says vaccine targeting Covid and flu shows promising results in early data

News Reporter
Last updated: April 20, 2022 4:56 pm
News Reporter
Share
6 Min Read
Novavax says vaccine targeting Covid and flu shows promising results in early data
SHARE

Contents
Novavax says vaccine targeting Covid and flu shows promising results in early data : Rashtra NewsCNBC Health & Science

Novavax says vaccine targeting Covid and flu shows promising results in early data : Rashtra News

#Novavax #vaccine #targeting #Covid #flu #shows #promising #results #early #data

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.

Patrick Van Katwijk | Getty Images

Novavax on Wednesday said its vaccine targeting both Covid-19 and the flu triggered an immune response similar to its stand-alone shots against each virus, in an early indication that a combination vaccine targeting both viruses could prove effective though further study is necessary.

Chief Medical Officer Filip Dubovsky, during a call with reporters, said the company’s early phase clinical trial found that up to 25 micrograms of the Covid formulation combined with up to 35 micrograms of the flu formulation triggered a promising level of protective antibodies.

“What we demonstrated in this study is we were able to get the immune responses really comparable to what the individual vaccines did prior to combination,” Dubovsky said.

Participants in the phase one trial had a median age of 59 and all of them had previously received Covid vaccines. Novavax is presenting the data at the World Vaccine Congress in Washington, D.C., on Wednesday.

Novavax plans to move forward with a phase two trial this year to confirm the appropriate dosing levels, and launch a phase three trial on efficacy during the 2023 flu season at the earliest, Dubovsky said.

Public health experts expect Covid to become a seasonal respiratory virus similar to the flu that will likely require annual vaccination because immunity from the shots wanes over time. The vaccine makers are racing to develop combination shots targeting both viruses to make it easier for people to get protected when Covid and the flu are circulating simultaneously.

“Combination vaccines are an attractive public health intervention,” Dubovsky said. “You are hitting two life-threatening diseases in one medical contact, giving a single vaccination.”

Novavax, an early participant in the U.S. government’s 2020 race to develop Covid shots, does not currently have an authorized vaccine in the U.S. The company asked the Food and Drug Administration to authorize its Covid vaccine in January. Dubovsky told reporters on Wednesday that the FDA is still reviewing Novavax’s application.

Novavax’s Covid vaccine uses different technology than Pfizer’s and Moderna’s shots, which rely on messenger RNA to turn human cells into factories that produce copies of the virus spike protein, inducing an immune response that fights Covid. The spike is the part of the virus that latches onto and invades human cells.

Novavax’s shots, on the other hand, fully synthesize the virus spike outside the human body. The genetic code for the spike is put into a baculovirus that infects insect cells, which then produce copies of the spike that are purified and extracted. The spike copy, which can’t replicate or cause Covid, is injected into people to induce an immune response against the virus.

The vaccine also uses an adjuvant that contains an extract purified from the bark of a tree in South America, to induce a broader immune response. The adjuvant has been used in licensed vaccines against malaria and shingles. Novavax’s stand-alone Covid shots consist of 5 micrograms of the spike copy and 50 micrograms of the adjuvant.

Novavax uses the same technology for its stand-alone flu vaccine candidate, which targets four strains of the virus.

While the up to 25 microgram Covid formulation in the combination vaccine is higher than the stand-alone shot, Dubovsky said it’s well within the range of the other FDA-licensed Covid vaccines, which have dosing levels between 50 and 100 micrograms.

The 25 microgram formulation tested in the combination vaccine trial was well tolerated and safe, Dubovsky said. The most common side effects were injection site pain, fatigue and headaches, he said.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

Latest Sports News | Latest Business News

( News Source :Except for the headline, this story has not been edited by Rashtra News staff and is published from a www.cnbc.com feed.)

Related searches :

  • top business news today
  • business news hindi
  • world business news
  • business news economic times
  • business news share market
  • business news live
  • business news india live
  • zee business news

Related

TAGGED: Biotech and Pharmaceuticals, Biotechnology, Breaking News: Business, business, business news, Coronavirus, Covid, Data, Disease outbreaks, early, Epidemics, flu, Health care industry, Moderna Inc, Novavax, Novavax Inc, Pandemics, Pfizer Inc, Politics, Promising, results, Shows, targeting, U.S. Economy, vaccine
Share This Article
Facebook Twitter Copy Link Print
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Surprise0
Joy0
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

You Might Also Like

Global Markets in Turmoil Amid Rising Inflation and Escalating Trade Tensions
BusinessFinanceStock MarketTop StoriesWorld

Global Markets in Turmoil Amid Rising Inflation and Escalating Trade Tensions

3 months ago
Hexaware and Novelty Group Forge Transformative Joint Venture
Press Release

Hexaware and Novelty Group Forge Transformative Joint Venture

1 year ago
Is Burger King Going Out of Business? A Tale of Two Flames (May 2023 – March 2024)
BusinessTop Stories

Is Burger King Going Out of Business? A Tale of Two Flames (May 2023 – March 2024)

1 year ago
KRBL Ltd. Committed to Grow Domestic Business Amidst Highest Ever Quarter Revenue in Q3FY24
Press Release

KRBL Ltd. Committed to Grow Domestic Business Amidst Highest Ever Quarter Revenue in Q3FY24

1 year ago

About RashtraNews.com

We're your comprehensive news source, covering a wide range of topics to empower you in all aspects of life. From navigating the world of finance (market trends, personal tips, loans, mortgages, credit) and legal matters (attorneys, lawyers), to staying ahead of the curve in technology (advancements, automobiles, business news) and education (careers, job opportunities, classes), RashtraNews.com keeps you informed.

Latest Updates

  • A Comprehensive Guide to Transportation, Logistics, and Relocation Services Across Cities
  • Global Markets in Turmoil Amid Rising Inflation and Escalating Trade Tensions
  • California Ballot Initiative Seeks to Prevent Unjust Health Insurance Denials
  • Millions of Travelers Risk Losing Insurance Coverage Over Simple Mistakes
  • Severe Thunderstorm Warnings Sweep Across USA: Tornado Threat Looms Over Oklahoma
  • ChatGPT Ghibli Art Generator: Create Studio Ghibli-Style Art with AI [2025]
  • Nida Rides India to Global Glory, 22-year to Become First Indian Lady to Compete at FEI Endurance World Championship for Seniors, Monpazier, France

Helpful Link

  • Automobile77
  • Business4,343
  • Crime129
  • Education4,542
  • Entertainment58
  • Finance5
  • India9,623
  • Insurance3
  • Legal News5
  • Lifestyle21
  • Media News79
  • Medical Education1
  • Politics4,340
  • Press Release5,319
  • Software100
  • Sports3,095
  • Stock Market2
  • Technology3,180
  • Top Stories7
  • World2,907

Contact Us

To send your suggestions to "Rashtra News", email: [email protected]

To send articles, news, or your opinions: [email protected]
For Business and other enquiries: [email protected]

If you‘ find any violation of the editorial code of conduct or have any other complaint about the content or video content published on "Rashtra News"’, you can send your complaint to our Grievance Officer by clicking on the Grievance Redressal link.

Follow US
©2011-2024 rashtranews.com
  • About Rashtra News
  • Ownership & funding
  • Corrections Policy
  • Fact Checking Policy
  • Privacy Policy
  • Terms of Use
  • Subscribe Now
  • Become a Author
  • Partnership With Us
Go to mobile version
adbanner
AdBlock Detected
Our site is an advertising supported site. Please whitelist to support our site.
Okay, I'll Whitelist
Welcome Back!

Sign in to your account

Lost your password?